Zonisamide
 OpenBabel02212023462D

 14 15  0  0  0  0  0  0  0  0999 V2000
   -0.7302   -2.4931    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0768   -2.3215    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.2483   -3.1285    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0947   -1.5146    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.8838   -2.1500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1387   -1.3654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6538   -0.6979    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1387   -0.0305    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.9233   -0.2854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6378    0.1271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3523   -0.2854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3523   -1.1104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6378   -1.5229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9233   -1.1104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  2  4  2  0  0  0  0
  2  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  0  0  0  0
  6 14  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
  9 14  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
M  END
>  <CdId>
237

>  <Mol Weight>
212.226

>  <Formula>
C8H8N2O3S

>  <ID>
T0267

>  <Name>
Zonisamide

>  <Synonyms>
AD 810;CI 912

>  <CAS>
68291-97-4

>  <Approved status>
FDA

>  <Disease>
Nervous system

>  <Indication>
Epilepsy; Parkinson'S Disease

>  <Pathways>
Membrane transporter/Ion channel; Metabolism

>  <Target>
Calcium Channel inhibitor; Carbonic Anhydrase inhibitor; Sodium Channel inhibitor

>  <Receptor>
Calcium Channel; Carbonic anhydrase; Sodium Channel

$$$$
